Whether Trametinib will be included in medical insurance and reimbursement ratio in 2025

Trametinib is an oral MEK1/2 inhibitor that inhibits BRAF by blocking the MEK kinase activity in the MAPK signaling pathway. Proliferation and promotion of apoptosis in V600 mutation-positive tumor cells. Clinically, trametinib is mainly used in combination with dabrafenib to treat BRAF V600 mutated melanoma, and can be used in some patients with non-small cell lung cancer and thyroid cancer, providing an important option for targeted therapy.

As of2025, trametinib has been officially launched in China and has been included in the national medical insurance system. This means that patients who qualify for medical insurance can enjoy partial reimbursement of costs, thereby easing the financial burden. The specific reimbursement ratio varies according to regional policies. Patients need to consult the local medical insurance reimbursement standards at the hospital or pharmacy to clarify the actual out-of-pocket amount and reimbursement process.

Domestic trametinib is available in two specifications: 0.5mg30 tablets and 2mg30 tablets. The former sells for about 3,000 to 4,000 yuan, and the latter sells for about 9,000 to 10,000 yuan. The actual payment amount after specific medical insurance reimbursement needs to be determined according to regional policies. In foreign markets, the Turkish original version 2mg*30 tablets sell for about 7,000 to 8,000 yuan, while the price of the trametinib generic drug approved by the Lao Ministry of Health is only about 1,000 yuan, and the drug ingredients are basically the same as the original drug, providing a viable option for patients with limited financial ability.

Clinically, trametinib is usually used in combination with dabrafenib to delay the development of drug resistance and improve efficacy. Patients need to regularly monitor blood pressure, liver function, electrocardiogram and eye conditions during medication to prevent adverse reactions such as hypertension, hepatotoxicity or retinal toxicity. For patients with different economic conditions, appropriate drugs can be selected based on domestic original drugs, medical insurance reimbursement status, and overseas or generic drug prices, and treatment courses can be reasonably arranged under the guidance of a doctor to ensure safe, continuous treatment and optimal efficacy.

Reference materials:https://www.drugs.com/